Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now early-phase tilt

Thrombocytopenia: early-phase trial registry

6 of 23 indexed Thrombocytopenia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #724 of 28,707 conditions by registered trial count.

23 US clinical trials · 6 currently recruiting · #724 of 28,707 conditions by registered trial count

Thrombocytopenia: 23 US clinical trials tracked, 6 recruiting.

Thrombocytopenia is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 3 of these trials.

Enrollment posture brief

Registry condition thrombocytopenia

OPEN 6 | RECR 26% | LATE 1 | EARLY 15 | RANK #724 | SPON 3

Nearest open-share peer: Parkinson's Disease (26% recruiting · 161 trials)

Breast Cancer Stage II47.8%Advanced Non-Small-Cell Lung39.1%Anxiety Disorder30.4%Barrett's Esophagus26.1%Thrombocytopenia (this)26%
Open-enrollment share among volume-matched conditions near Thrombocytopenia

Thrombocytopenia lists 6 open slots (26% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Thrombocytopenia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Thrombocytopenia is recruiting below its size-band peers.

    6 of 23 indexed trials (26.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Thrombocytopenia trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 3 of 23 trials (13%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Most Thrombocytopenia trials plan to enrol fewer than 100 people.

    Median target enrolment is 48 among the 21 trials that report a genuine target (sentinel values excluded). 16 of those (76.2%) plan for fewer than 100 participants.

  4. Thrombocytopenia research is mostly interventional.

    22 interventional and 1 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 210Phase 41

Open and recent trials

23 total, page 1 of 1

RECRUITING NA 2,433 participants

Neonatal Platelet Transfusion Threshold Trial

NICHD Neonatal Research Network

NCT06676904

RECRUITING NA 1,100 participants

Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury

University of Colorado, Denver

NCT06349577

RECRUITING NA 132 participants

Platelet-Directed Whole Blood Transfusion Strategy for Malaria

Johns Hopkins Bloomberg School of Public Health

NCT05711485

RECRUITING Phase 2 50 participants

Luspatercept for Clonal Cytopenias of Uncertain Significance

Weill Medical College of Cornell University

NCT06788691

RECRUITING Phase 2 40 participants

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

NCT07025512

RECRUITING Early Phase 1 30 participants

Apixaban in Thrombocytopenia

Rushad Patell

NCT06886516

ACTIVE NOT RECRUITING Phase 2 11 participants

Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma

Memorial Sloan Kettering Cancer Center

NCT04673266

COMPLETED NA 1,543 participants

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

University of Utah

NCT05634005

COMPLETED NA 446 participants

Effects of a Platelet Transfusion Best Practices Alert

Stanford University

NCT04155775

COMPLETED Phase 2 75 participants

SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

GlaxoSmithKline

NCT00110799

COMPLETED Phase 2 64 participants

Eltrombopag for Post Transplant Thrombocytopenia

M.D. Anderson Cancer Center

NCT01000051

COMPLETED Phase 2 63 participants

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

NCT00413283

COMPLETED Phase 2 50 participants

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

SWOG Cancer Research Network

NCT00002665

COMPLETED Phase 1 48 participants

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

Eisai

NCT02039076

COMPLETED Phase 1 40 participants

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

University of California, San Francisco

NCT00305708

COMPLETED Phase 2 24 participants

Daclizumab to Treat Chronic Immune Thrombocytopenia

National Institutes of Health Clinical Center (CC)

NCT00049725

COMPLETED Phase 4 24 participants

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

Encysive Pharmaceuticals

NCT00039858

COMPLETED Phase 2 21 participants

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

M.D. Anderson Cancer Center

NCT01428635

COMPLETED 20 participants

Thrombopoietin Levels and Platelet Transfusion in Neonates

Christiana Care Health Services

NCT00549484

COMPLETED Early Phase 1 15 participants

TPO-Mimetic Use in Children for Hematopoietic Failure

Anjali Sharathkumar

NCT04478227

COMPLETED Phase 2 10 participants

Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia

National Heart, Lung, and Blood Institute (NHLBI)

NCT02298933

COMPLETED Phase 1

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Drexel University College of Medicine

NCT00003619

COMPLETED NA

Stem Cell Transplantation (SCT) for Genetic Diseases

National Center for Research Resources (NCRR)

NCT00004378

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 10
Phase 4 1

Named interventions

Most-linked intervention names on Thrombocytopenia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

busulfan Drug
2 trials
cytarabine Drug
2 trials
Romiplostim Drug
2 trials
Placebo Drug
2 trials
SB497115 Drug
1 trials
Clinical Decision Support Behavioral
1 trials
Romiplostim Biological
1 trials
Daclizumab Drug
1 trials

US sites by state

Facility locations filed on Thrombocytopenia trials. A trial with sites in several states counts in each.

California 8 trials
Texas 5 trials
New York 4 trials
Massachusetts 4 trials
Colorado 4 trials
Utah 3 trials
Pennsylvania 3 trials
Maryland 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Thrombocytopenia page

23 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thrombocytopenia condition card totals 23 registered trials; most-linked intervention busulfan; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.